SNU-5 In Vivo Tumorigenesis Assay

This assay is to provide SNU-5-based In Vivo Tumorigenesis Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNU-5

Human

SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C.
Derived from metastatic site, ascites

Gastric Carcinoma

Oncology

In Vivo Tumorigenesis Assay

SNU-5-cell based In Vivo Tumorigenesis Assay

Tumorigenicity is defined the property of a cell to form tumors when inoculated into an immunosuppressed animal model. Generally, test cells and tumor cells as positive control are administered subcutaneously into immunosuppressed nude mice. The number of animals developing tumors are compared with a positive control reference cell line.

Oncology In Vivo Assays